What You Should Know:
– Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic collaboration with medical artificial intelligence (“AI”) company PulseAI to enhance the Company’s recently acquired continuous glucose monitor (CGM) biosensor technology.
– Under this collaboration, Trinity Biotech will provide a pool of unique multi-parameter CGM datasets from Trinity Biotech’s existing biosensor database to PulseAI.
Enhancing Trinity Biotech’s CGM Solution with AI-Driven Health Analytics and PulseAI Collaboration
This data will support Trinity Biotech’s AI-driven health analytics platform, enhancing their needle-free, reusable CGM solution for global launch. PulseAI, experts in medical AI, have collaborated with Mayo Clinic to train algorithms on large-scale medical sensor datasets.
Trinity Biotech Chief Technology Officer, Dr Gary Keating, stated, “This collaboration will deliver important insights as we develop our AI driven analytical platform. This project will harness the potential of using additional personalised data from in, on and around the body to enhance the utility of continuous glucose measurements, improving the user experience, increasing satisfaction, and providing superior metabolic insights.”
